Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

931.09 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,585
Open 931.09
Bid (Size) 945.00 (40)
Ask (Size) 948.99 (200)
Prev. Close 931.09
Today's Range 931.09 - 931.09
52wk Range 623.78 - 1,133.95
Shares Outstanding 956,580,893
Dividend Yield 0.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why AC Immune Stock Zoomed Almost 15% Higher Today ↗
It's getting a cash infusion from its giant pharmaceutical partner. 
Via The Motley Fool

Performance

YTD
-13.8%
-13.8%
1 Month
-7.7%
-7.7%
3 Month
-12.5%
-12.5%
6 Month
+10.4%
+10.4%
1 Year
+28.7%
+28.7%

More News

Read More
News headline image
Great News for Eli Lilly Stock Investors! ↗
Via The Motley Fool
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets MASLD and GLP-1 Imaging Bottleneck With TAEUS® as Stocks Under $5 Gain Attention Inside
Via AB Newswire
News headline image
Is Eli Lilly Stock a Buy After a Brand New Approval? ↗
Via The Motley Fool
News headline image
The AI Engine: S&P 500 Defies Gravity with 13.3% Q4 Growth as Tech Titans Carry the Weight
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
Via TheNewswire.com
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
Via MarketMinute
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
Via MarketMinute
Topics Artificial Intelligence
News headline image
Productivity Surge and Falling Jobless Claims: The New U.S. Labor Paradigm
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
S&P 500 Snaps Five-Week Slump with 3.4% Tech-Led Surge Amid Middle East De-escalation Hopes
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
Via MarketMinute
Topics Economy World Trade
News headline image
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗
Via MarketBeat
News headline image
2 Cash-Producing Stocks with Impressive Fundamentals and 1 We Brush Off
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Via StockStory
Topics Artificial Intelligence
News headline image
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗
Via The Motley Fool
News headline image
The Next Big AI Winner Might Not Be a Tech Company
Via Barchart.com
Topics Artificial Intelligence
News headline image
The Second-Best Performing Vanguard ETF Over the Last Decade Is Issuing a 5-For-1 Stock Split. Here's Why It's a Screaming Buy in April. ↗
Via The Motley Fool
Topics ETFs
News headline image
Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗
Via The Motley Fool
News headline image
Where Will Viking Therapeutics Stock Be in 10 Years? ↗
Via The Motley Fool
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
Via MarketMinute
Topics Intellectual Property
News headline image
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy ↗
Via Benzinga
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
Via MarketMinute
Topics Economy Government Lawsuit

Frequently Asked Questions

Is Eli Lilly publicly traded?
Yes, Eli Lilly is publicly traded.
What exchange does Eli Lilly trade on?
Eli Lilly trades on the New York Stock Exchange
What is the ticker symbol for Eli Lilly?
The ticker symbol for Eli Lilly is LLY on the New York Stock Exchange
What is the current price of Eli Lilly?
The current price of Eli Lilly is 931.09
When was Eli Lilly last traded?
The last trade of Eli Lilly was at 04/07/26 07:00 PM ET
What is the market capitalization of Eli Lilly?
The market capitalization of Eli Lilly is 890.66B
How many shares of Eli Lilly are outstanding?
Eli Lilly has 891B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.